CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$56.24 USD
+1.68 (3.08%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $56.21 -0.03 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRSP 56.24 +1.68(3.08%)
Will CRSP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
Other News for CRSP
3 Gene Editing Stocks Shaping the Future of Medicine
3 Gene Editing Stocks That Could Grow Your Wealth
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Crispr Therapeutics call volume above normal and directionally bullish
Blue Chips, Small Caps Extending Their Breakout